Spectrum Pharma's blood cancer drug meets trial goal

(Reuters) - Spectrum Pharmaceuticals Inc said a mid-stage trial of its experimental blood cancer drug met the main goal of reducing the size of tumors. The biotechnology company's shares, which have fallen about 22 percent over the past 12 months, were up about 3 percent at $11.60 in morning trade on the Nasdaq and touched a high of $11.75 . The drug, belinostat, was tested in patients with relapsed or refractory peripheral T-Cell lymphoma (PTCL), and who had failed to respond to at least one therapy. The company said it expects to file a marketing application with U.S. ... via Health News Headlines - Yahoo! News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/12/spectrum-pharma-blood-cancer-drug-meets_21.html